SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
采用含单磷酰脂质A和QS-21的Army脂质体配方佐剂的SARS-CoV-2重组刺突铁蛋白纳米颗粒疫苗:一项I期、随机、双盲、安慰剂对照、首次人体临床试验
期刊:Lancet Microbe
影响因子:20.4
doi:10.1016/S2666-5247(23)00410-X
Ober Shepherd, Brittany L; Scott, Paul T; Hutter, Jack N; Lee, Christine; McCauley, Melanie D; Guzman, Ivelese; Bryant, Christopher; McGuire, Sarah; Kennedy, Jessie; Chen, Wei-Hung; Hajduczki, Agnes; Mdluli, Thembi; Valencia-Ruiz, Anais; Amare, Mihret F; Matyas, Gary R; Rao, Mangala; Rolland, Morgane; Mascola, John R; De Rosa, Stephen C; McElrath, M Juliana; Montefiori, David C; Serebryannyy, Leonid; McDermott, Adrian B; Peel, Sheila A; Collins, Natalie D; Joyce, M Gordon; Robb, Merlin L; Michael, Nelson L; Vasan, Sandhya; Modjarrad, Kayvon